# Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

> **NCT00278824** · PHASE2 · TERMINATED · sponsor: **ZARS Pharma Inc.** · enrollment: 109 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Matrix Transdermal Fentanyl/CHADD Drug Delivery System
- **DRUG:** Placebo Patch

## Key facts

- **NCT ID:** NCT00278824
- **Lead sponsor:** ZARS Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 109 (ACTUAL)
- **Why stopped:** Difficulty identifying and enrolling eligible patients
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278824, "Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00278824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*